Skip to main content

Table 2 Association of statin treatment with continuous outcome variables

From: Associations between statins and COPD: a systematic review

Study Outcome Parameter estimate and 95% confidence interval
Mortality 2° to COPD   
Ishida W, et al., Japan, 2007 [23] Decreased mortality 2° to COPD in statin users Inverse correlation between statin prescriptions dispensed and mortality due COPD by prefecture, p < 0.0001
Respiratory-related urgent care   
Keddissi JI, et al., USA, 2007 [26] Reduction in respiratory-related emergency-department-visits and/or hospitalizations in statin users Incidence of respiratory related urgent care, obstructive spirometry group 0.12 ± 0.29/patient-yrs in statin users versus 0.19 ± 0.32/patient-yrs in control, p = 0.02
Lung function   
Keddissi JI, et al., USA, 2007 [26] Lower decline in FEV1 and FVC/yr in statin users Obstructive spirometry group
change in FEV1 +5 ± 207 ml/yr in statin users
change in FEV1–86 ± 168 ml/yr in control (p < 0.0001)
change in FVC +33 ± 452 ml/yr in statin users
change in FVC-150 ± 328 ml/yr in control (p < 0.0001)
Lee T-M, et al., Taiwan, 2008 [19] No difference in pulmonary function parameters in statin users Pravastatin group: FEV1% at baseline 51 ± 18, at follow-up 55 ± 19
Placebo group: FEV1% at baseline 56 ± 13, at follow-up 55 ± 14, p > 0.05
Exercise capacity   
Lee T-M, et al., Taiwan, 2008 [19] Improvement in exercise time in statin users Pravastatin group: exercise time in s at baseline 599 ± 323, at follow-up 922 ± 328
Placebo group: exercise time in s at baseline 608 ± 273, at follow-up 609 ± 180, p < 0.05
Borg dyspnea score after exercise tests   
Lee T-M, et al., Taiwan, 2008 [19] Lesser degree of dyspnea after exercise in statin users Pravastatin group: Borg dyspnea score at baseline 7.0 ± 0.8, at follow-up 4.0 ± 0.7
Placebo group: Borg dyspnea score at baseline 6.9 ± 0.8, at follow-up 6.9 ± 1.0, p < 0.05
CRP/IL-6 levels   
Lee T-M, et al., Taiwan, 2008 [19] Decrease in CRP/IL-6 levels in statin users Pravastatin group: CRP (mg/l) at baseline 3.94 ± 3.54, at follow-up 3.85 ± 2.56
Placebo group: CRP (mg/l) at baseline 4.06 ± 2.67, at follow-up 2.66 ± 2.49, p < 0.05